Orthodontic Headgear
The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More
Global Orphan Diseases Market Research Report 2023
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Therapy Area Type
1.2.1 Global Orphan Diseases Market Size Growth Rate by Therapy Area Type: 2017 VS 2021 VS 2028
1.2.2 Ocology
1.2.3 Hematology
1.2.4 Neurology
1.2.5 Endocrinology
1.2.6 Cardiovascular
1.2.7 Respiratory
1.2.8 Immunotherapy
1.2.9 Others
1.3 Market by Application
1.3.1 Global Orphan Diseases Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Orphan Diseases Market Perspective (2017-2028)
2.2 Orphan Diseases Growth Trends by Region
2.2.1 Orphan Diseases Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Orphan Diseases Historic Market Size by Region (2017-2022)
2.2.3 Orphan Diseases Forecasted Market Size by Region (2023-2028)
2.3 Orphan Diseases Market Dynamics
2.3.1 Orphan Diseases Industry Trends
2.3.2 Orphan Diseases Market Drivers
2.3.3 Orphan Diseases Market Challenges
2.3.4 Orphan Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Orphan Diseases Players by Revenue
3.1.1 Global Top Orphan Diseases Players by Revenue (2017-2022)
3.1.2 Global Orphan Diseases Revenue Market Share by Players (2017-2022)
3.2 Global Orphan Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Orphan Diseases Revenue
3.4 Global Orphan Diseases Market Concentration Ratio
3.4.1 Global Orphan Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Orphan Diseases Revenue in 2021
3.5 Orphan Diseases Key Players Head office and Area Served
3.6 Key Players Orphan Diseases Product Solution and Service
3.7 Date of Enter into Orphan Diseases Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Orphan Diseases Breakdown Data by Therapy Area Type
4.1 Global Orphan Diseases Historic Market Size by Therapy Area Type (2017-2022)
4.2 Global Orphan Diseases Forecasted Market Size by Therapy Area Type (2023-2028)
5 Orphan Diseases Breakdown Data by Application
5.1 Global Orphan Diseases Historic Market Size by Application (2017-2022)
5.2 Global Orphan Diseases Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Orphan Diseases Market Size (2017-2028)
6.2 North America Orphan Diseases Market Size by Country (2017-2022)
6.3 North America Orphan Diseases Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Orphan Diseases Market Size (2017-2028)
7.2 Europe Orphan Diseases Market Size by Country (2017-2022)
7.3 Europe Orphan Diseases Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Orphan Diseases Market Size (2017-2028)
8.2 Asia-Pacific Orphan Diseases Market Size by Country (2017-2022)
8.3 Asia-Pacific Orphan Diseases Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Orphan Diseases Market Size (2017-2028)
9.2 Latin America Orphan Diseases Market Size by Country (2017-2022)
9.3 Latin America Orphan Diseases Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Orphan Diseases Market Size (2017-2028)
10.2 Middle East & Africa Orphan Diseases Market Size by Country (2017-2022)
10.3 Middle East & Africa Orphan Diseases Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Orphan Diseases Introduction
11.1.4 Bristol-Myers Squibb Revenue in Orphan Diseases Business (2017-2022)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Orphan Diseases Introduction
11.2.4 Novartis Revenue in Orphan Diseases Business (2017-2022)
11.2.5 Novartis Recent Development
11.3 Celgene
11.3.1 Celgene Company Detail
11.3.2 Celgene Business Overview
11.3.3 Celgene Orphan Diseases Introduction
11.3.4 Celgene Revenue in Orphan Diseases Business (2017-2022)
11.3.5 Celgene Recent Development
11.4 Roche
11.4.1 Roche Company Detail
11.4.2 Roche Business Overview
11.4.3 Roche Orphan Diseases Introduction
11.4.4 Roche Revenue in Orphan Diseases Business (2017-2022)
11.4.5 Roche Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Orphan Diseases Introduction
11.5.4 Pfizer Revenue in Orphan Diseases Business (2017-2022)
11.5.5 Pfizer Recent Development
11.6 Alexion
11.6.1 Alexion Company Detail
11.6.2 Alexion Business Overview
11.6.3 Alexion Orphan Diseases Introduction
11.6.4 Alexion Revenue in Orphan Diseases Business (2017-2022)
11.6.5 Alexion Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Detail
11.7.2 Sanofi Business Overview
11.7.3 Sanofi Orphan Diseases Introduction
11.7.4 Sanofi Revenue in Orphan Diseases Business (2017-2022)
11.7.5 Sanofi Recent Development
11.8 Vertex Pharmaceuticals
11.8.1 Vertex Pharmaceuticals Company Detail
11.8.2 Vertex Pharmaceuticals Business Overview
11.8.3 Vertex Pharmaceuticals Orphan Diseases Introduction
11.8.4 Vertex Pharmaceuticals Revenue in Orphan Diseases Business (2017-2022)
11.8.5 Vertex Pharmaceuticals Recent Development
11.9 GlaxoSmithKline
11.9.1 GlaxoSmithKline Company Detail
11.9.2 GlaxoSmithKline Business Overview
11.9.3 GlaxoSmithKline Orphan Diseases Introduction
11.9.4 GlaxoSmithKline Revenue in Orphan Diseases Business (2017-2022)
11.9.5 GlaxoSmithKline Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Orphan Diseases Introduction
11.10.4 Merck Revenue in Orphan Diseases Business (2017-2022)
11.10.5 Merck Recent Development
11.11 Abbvie
11.11.1 Abbvie Company Detail
11.11.2 Abbvie Business Overview
11.11.3 Abbvie Orphan Diseases Introduction
11.11.4 Abbvie Revenue in Orphan Diseases Business (2017-2022)
11.11.5 Abbvie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Orphan Diseases Market Size Growth Rate by Therapy Area Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Ocology
Table 3. Key Players of Hematology
Table 4. Key Players of Neurology
Table 5. Key Players of Endocrinology
Table 6. Key Players of Cardiovascular
Table 7. Key Players of Respiratory
Table 8. Key Players of Immunotherapy
Table 9. Key Players of Others
Table 10. Global Orphan Diseases Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 11. Global Orphan Diseases Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 12. Global Orphan Diseases Market Size by Region (2017-2022) & (US$ Million)
Table 13. Global Orphan Diseases Market Share by Region (2017-2022)
Table 14. Global Orphan Diseases Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 15. Global Orphan Diseases Market Share by Region (2023-2028)
Table 16. Orphan Diseases Market Trends
Table 17. Orphan Diseases Market Drivers
Table 18. Orphan Diseases Market Challenges
Table 19. Orphan Diseases Market Restraints
Table 20. Global Orphan Diseases Revenue by Players (2017-2022) & (US$ Million)
Table 21. Global Orphan Diseases Market Share by Players (2017-2022)
Table 22. Global Top Orphan Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Diseases as of 2021)
Table 23. Ranking of Global Top Orphan Diseases Companies by Revenue (US$ Million) in 2021
Table 24. Global 5 Largest Players Market Share by Orphan Diseases Revenue (CR5 and HHI) & (2017-2022)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Orphan Diseases Product Solution and Service
Table 27. Date of Enter into Orphan Diseases Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Orphan Diseases Market Size by Therapy Area Type (2017-2022) & (US$ Million)
Table 30. Global Orphan Diseases Revenue Market Share by Therapy Area Type (2017-2022)
Table 31. Global Orphan Diseases Forecasted Market Size by Therapy Area Type (2023-2028) & (US$ Million)
Table 32. Global Orphan Diseases Revenue Market Share by Therapy Area Type (2023-2028)
Table 33. Global Orphan Diseases Market Size by Application (2017-2022) & (US$ Million)
Table 34. Global Orphan Diseases Revenue Market Share by Application (2017-2022)
Table 35. Global Orphan Diseases Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 36. Global Orphan Diseases Revenue Market Share by Application (2023-2028)
Table 37. North America Orphan Diseases Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Orphan Diseases Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Orphan Diseases Market Size by Country (2017-2022) & (US$ Million)
Table 40. Europe Orphan Diseases Market Size by Country (2023-2028) & (US$ Million)
Table 41. Asia-Pacific Orphan Diseases Market Size by Region (2017-2022) & (US$ Million)
Table 42. Asia-Pacific Orphan Diseases Market Size by Region (2023-2028) & (US$ Million)
Table 43. Latin America Orphan Diseases Market Size by Country (2017-2022) & (US$ Million)
Table 44. Latin America Orphan Diseases Market Size by Country (2023-2028) & (US$ Million)
Table 45. Middle East & Africa Orphan Diseases Market Size by Country (2017-2022) & (US$ Million)
Table 46. Middle East & Africa Orphan Diseases Market Size by Country (2023-2028) & (US$ Million)
Table 47. Bristol-Myers Squibb Company Detail
Table 48. Bristol-Myers Squibb Business Overview
Table 49. Bristol-Myers Squibb Orphan Diseases Product
Table 50. Bristol-Myers Squibb Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 51. Bristol-Myers Squibb Recent Development
Table 52. Novartis Company Detail
Table 53. Novartis Business Overview
Table 54. Novartis Orphan Diseases Product
Table 55. Novartis Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Celgene Company Detail
Table 58. Celgene Business Overview
Table 59. Celgene Orphan Diseases Product
Table 60. Celgene Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 61. Celgene Recent Development
Table 62. Roche Company Detail
Table 63. Roche Business Overview
Table 64. Roche Orphan Diseases Product
Table 65. Roche Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 66. Roche Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Orphan Diseases Product
Table 70. Pfizer Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Alexion Company Detail
Table 73. Alexion Business Overview
Table 74. Alexion Orphan Diseases Product
Table 75. Alexion Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 76. Alexion Recent Development
Table 77. Sanofi Company Detail
Table 78. Sanofi Business Overview
Table 79. Sanofi Orphan Diseases Product
Table 80. Sanofi Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 81. Sanofi Recent Development
Table 82. Vertex Pharmaceuticals Company Detail
Table 83. Vertex Pharmaceuticals Business Overview
Table 84. Vertex Pharmaceuticals Orphan Diseases Product
Table 85. Vertex Pharmaceuticals Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 86. Vertex Pharmaceuticals Recent Development
Table 87. GlaxoSmithKline Company Detail
Table 88. GlaxoSmithKline Business Overview
Table 89. GlaxoSmithKline Orphan Diseases Product
Table 90. GlaxoSmithKline Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 91. GlaxoSmithKline Recent Development
Table 92. Merck Company Detail
Table 93. Merck Business Overview
Table 94. Merck Orphan Diseases Product
Table 95. Merck Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 96. Merck Recent Development
Table 97. Abbvie Company Detail
Table 98. Abbvie Business Overview
Table 99. Abbvie Orphan DiseasesProduct
Table 100. Abbvie Revenue in Orphan Diseases Business (2017-2022) & (US$ Million)
Table 101. Abbvie Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Orphan Diseases Market Share by Therapy Area Type: 2021 VS 2028
Figure 2. Ocology Features
Figure 3. Hematology Features
Figure 4. Neurology Features
Figure 5. Endocrinology Features
Figure 6. Cardiovascular Features
Figure 7. Respiratory Features
Figure 8. Immunotherapy Features
Figure 9. Others Features
Figure 10. Global Orphan Diseases Market Share by Application in 2021 & 2028
Figure 11. Hospital Pharmacy Case Studies
Figure 12. Retail Pharmacy Case Studies
Figure 13. Others Case Studies
Figure 14. Orphan Diseases Report Years Considered
Figure 15. Global Orphan Diseases Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 16. Global Orphan Diseases Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 17. Global Orphan Diseases Market Share by Region: 2021 VS 2028
Figure 18. Global Orphan Diseases Market Share by Players in 2021
Figure 19. Global Top Orphan Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Orphan Diseases as of 2021)
Figure 20. The Top 10 and 5 Players Market Share by Orphan Diseases Revenue in 2021
Figure 21. North America Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 22. North America Orphan Diseases Market Share by Country (2017-2028)
Figure 23. United States Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Canada Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Europe Orphan Diseases Market Share by Country (2017-2028)
Figure 27. Germany Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. France Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. U.K. Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Italy Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Russia Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Nordic Countries Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Asia-Pacific Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Orphan Diseases Market Share by Region (2017-2028)
Figure 35. China Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Latin America Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Orphan Diseases Market Share by Country (2017-2028)
Figure 43. Mexico Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Brazil Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Middle East & Africa Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Orphan Diseases Market Share by Country (2017-2028)
Figure 47. Turkey Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Saudi Arabia Orphan Diseases Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 50. Novartis Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 51. Celgene Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 52. Roche Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 53. Pfizer Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 54. Alexion Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 55. Sanofi Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 56. Vertex Pharmaceuticals Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 57. GlaxoSmithKline Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 58. Merck Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 59. Abbvie Revenue Growth Rate in Orphan Diseases Business (2017-2022)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bristol-Myers Squibb Novartis Celgene Roche Pfizer Alexion Sanofi Vertex Pharmaceuticals GlaxoSmithKline Merck Abbvie